It was also found that CRL4DCAF2 inhibits the non-canonical activity of NF-κB in a NIK-dependent manner and ultimately reduces the production of interleukin 23 (IL-23), which can be a potential therapeutic target for psoriasis (23). Here, IL37 is linked to psoriasis.